Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-212 combination trial in advanced solid tumors
2025-524620-22-00Phase 2Authorised
- Sponsor
- Orion Corporation
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of ODM-212 in Nonhematologic neoplasms (4 arms), sponsored by Orion Corporation. Primary endpoints: Safety and tolerability and Safety. Planned start Jun 2026; status: authorised.
02
Drugs
ODM-212
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-524620-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524620-22-00.